UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
10.14
-1.00 (-8.98%)
At close: May 13, 2025, 4:00 PM
10.35
+0.21 (2.07%)
Pre-market: May 14, 2025, 7:15 AM EDT
UroGen Pharma Revenue
UroGen Pharma had revenue of $20.25M in the quarter ending March 31, 2025, with 7.84% growth. This brings the company's revenue in the last twelve months to $91.87M, up 8.98% year-over-year. In the year 2024, UroGen Pharma had annual revenue of $90.40M with 9.29% growth.
Revenue (ttm)
$91.87M
Revenue Growth
+8.98%
P/S Ratio
5.02
Revenue / Employee
$390,940
Employees
235
Market Cap
467.53M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 90.40M | 7.69M | 9.29% |
| Dec 31, 2023 | 82.71M | 18.36M | 28.52% |
| Dec 31, 2022 | 64.36M | 16.32M | 33.96% |
| Dec 31, 2021 | 48.04M | 36.24M | 307.17% |
| Dec 31, 2020 | 11.80M | 11.78M | 65,450.00% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
URGN News
- 1 day ago - UroGen Pharma Ltd. (URGN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update - Business Wire
- 6 days ago - UroGen Announces FDA Advisory Committee for UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer - Business Wire
- 12 days ago - UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - Business Wire
- 15 days ago - UroGen Pharma Touts Four-Year Response With Urothelial Cancer Drug Study, Highlights Potential For Bladder Cancer Candidates - Benzinga
- 16 days ago - OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment - Business Wire
- 16 days ago - New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC - Business Wire
- 16 days ago - New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC - Business Wire